NCT06424067View on ClinicalTrials.gov

Phase 2 Study of Fingolimod in Lung Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Non Small Cell Lung CancerSmall-cell Lung Cancer
Interventions
DRUG

Fingolimod 0.5 milligram (mg) [Gilenya]

Oral fingolimod will be administered at a dose of 0.5 mg once a day.

Trial Locations (1)

29425

RECRUITING

Hollings Cancer Center at Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER